The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-25. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Cnidarians form a phylum of animals that are more complex than sponges, about as complex as ctenophores (comb jellies), and less complex than bilaterians, which include almost all other animals. Both cnidarians and ctenophores are more complex than sponges as they have: cells bound by inter-cell connections and carpet-like basement membranes; muscles; nervous systems; and some have sensory organs. Cnidarians are distinguished from all other animals by having cnidocytes that fire harpoon-like structures that are mainly used to capture prey. In some species, cnidocytes can also be used as anchors. Cnidarians are also distinguished by the fact that they have only one opening in their body for ingestion and excretion i.e. they do not have a separate mouth and anus. Like sponges and ctenophores, cnidarians have two main layers of cells that sandwich a middle layer of jelly-like material, which is called the mesoglea in cnidarians; more complex animals have three main cell layers and no intermediate jelly-like layer. Hence, cnidarians and ctenophores have traditionally been labelled diploblastic, along with sponges. However, both cnidarians and ctenophores have a type of muscle that, in more complex animals, arises from the middle cell layer. As a result, some recent text books classify ctenophores as triploblastic, and it has been suggested that cnidarians evolved from triploblastic ancestors.
== Development == Valve developed Half-Life 2 (2004) over six years using its new game engine, Source. Instead of beginning work on a full sequel, Valve decided to create a series of episodic sequels. The designer Robin Walker said the team had become comfortable with their tools, and wanted to capitalize on their experience instead of developing new technologies. Valve's president, Gabe Newell, said customers would be happier with a new Half-Life game delivered in a shorter time rather than waiting years for another "monolithic product". In April 2005, Valve announced the game under the working title Aftermath. The title Episode One was announced in February 2006. In May, Valve announced that Episode One would be the first in a trilogy of episodic games to be released over the following two years. Newell said he considered the trilogy the equivalent of Half-Life 3. According to Newell, whereas the original Half-Life (1998) saw the G-Man transform Freeman into his tool, and Half-Life 2 saw Freeman being used by G-Man, the episodes would see G-Man lose control. While the plots and dialogue of Half-Life and Half-Life 2 were written solely by Marc Laidlaw, the Half-Life 2 episodes were written by Laidlaw and the new employees Chet Faliszek and Erik Wolpaw. Valve's focus was character development, particularly that of Gordon's companion Alyx, who accompanies the player for most of Episode One. Walker said it was ironic that the player spends most of Half-Life 2 alone despite the themes of "characters and other people".
=== EU risk assessments === In 2002 the EU Scientific Committee on Veterinary Measures relating to Public Health (SCVPH) claimed that the use of beef growth hormones posed a potential health risk, and in 2003 the EU enacted Directive 2003/74/EC to amend its ban, but the US and Canada objected that the EU had not met WTO standards for scientific risk assessment. The EC claimed that the hormones remain in the tissue, specifically 17-beta estradiol. However, the EC found no clear link to health risks in humans for the other five hormones. The EC reported that high amounts of hormones had been found in areas around dense cattle lots. This increase in hormones in groundwater affected waterways and nearby wild fish. Hormone contamination of North American waterways would not, however, have any health impacts on European consumers.
Sources: en.wikipedia.org
=== Craniofacial syndromes === Of substantial recent interest is the idea that there is a general human tendency towards developing short lower jaws (neoteny) is a major cause of OSA through a combined condition called glossoptosis. The posterior "normal" tongue is displaced backwards by a smaller "abnormal" anterior tongue and lower jaw. In much the same way, a narrow upper jaw will also contribute to OSA due to its relation to airway volume. A narrower upper jaw results in narrower nasal passages and a narrower throat; this also appears to be why so many OSA patients experience nasal congestion, especially while lying down. Maxillofacial surgeons see many effects of small lower jaws, including crowded teeth, malocclusions, as well as OSA – all of which are treatable by surgical operations that increase and normalise jaw size. Operations such as custom BIMAX, GenioPaully, and IMDO (in adolescence) offer a valid medical option that replaces all traditional forms of OSA treatment – including CPAP, Mandibular Advancement Splints, tonsillectomy, and UPPP. There are patterns of unusual facial features that occur in recognizable syndromes. Some of these craniofacial syndromes are genetic, and others are from unknown causes. In many craniofacial syndromes, unusual features involve the nose, mouth, and jaw, or resting muscle tone, and put the individual at risk for OSA. Down syndrome is one such syndrome. In this chromosomal abnormality, several features combine to make the presence of obstructive sleep apnea more likely.
The Drug Prevention Network of Canada states that harm reduction has "...come to represent a philosophy in which illicit substance use is seen as largely unpreventable, and increasingly, as a feasible and acceptable lifestyle as long as use is not 'problematic'", an approach which can increase "acceptance of drug use into the mainstream of society". They say harm reduction "...sends the wrong message to ... children and youth" about drug use. In 2008, the Declaration of World Forum Against Drugs criticized harm reduction policies that "...accept drug use and do not help drug users to become free from drug abuse", which the group say undermines "...efforts to limit the supply of and demand for drugs." They state that harm reduction should not lead to less efforts to reduce drug demand. Pope Benedict XVI criticised harm reduction policies with regards to HIV/AIDS, saying that it was "a tragedy that cannot be overcome by money alone, that cannot be overcome through the distribution of condoms, which even aggravates the problems". This position was in turn widely criticised for misrepresenting and oversimplifying the role of condoms in preventing infections. A March 2025 study exploring the association of safer supply and decriminalization policy with opioid overdose outcomes in British Columbia, Canada, found that neither policy "appeared to mitigate the opioid crisis, and both were associated with an increase in opioid overdose hospitalizations."
Kumārajīva is known to have travelled repeatedly between Kucha and Kashmir around this time, and he may have been instrumental, among many others, in the transmission of this art. The structural prototype of the cave may be Kara Tepe in Bactria. The flat, well-delineated surfaces of the paintings remind of the Roman Opus sectile technique, which prospered circa 331–359 CE.
==== France ==== In France, several recent laws have established a protection regime for whistleblowers. Before 2016, there were several laws in force which created disparate legislation with sector-specific regimes. The 2016 law on transparency, the fight against corruption and modernization of economic life (known as the "Sapin 2 Law") provides for the first time a single legal definition of whistleblowers in France. It defines him or her as "an individual who discloses or reports, in a disinterested manner and in good faith, a crime or an offence, a serious and manifest breach of an international commitment duly ratified or approved by France, a unilateral act of an international organization adopted based on such a commitment, of the law or regulations, or a serious threat or harm to general interest, which he or she has become personally aware of." It excludes certain professional secrets such as national defense secrecy, medical secrecy or the secrecy of relations between a lawyer and his client. In 2022, two laws were passed to transpose the European Directive 2019/1937 of 23 October 2019 on the protection of persons who report breaches of Union law. One of them strengthens the role of the Défenseur des droits – the French ombudsman – tasked with advising and protecting whistleblowers. The second amends the Sapin 2 law to bring it into line with the directive and adds substantial guarantees not included in the directive, among which:
Sources: en.wikipedia.org
1978 Genentech produces biosynthetic human insulin in Escherichia coli bacteria using recombinant DNA techniques, licenses to Eli Lilly 1981 Novo Nordisk chemically and enzymatically converts porcine to human insulin 1982 Genentech synthetic human insulin (above) approved 1983 Eli Lilly and Company produces biosynthetic human insulin with recombinant DNA technology, Humulin 1985 Axel Ullrich sequences a human cell membrane insulin receptor. 1988 Novo Nordisk produces recombinant biosynthetic human insulin 1996 Lilly Humalog "lispro" insulin analogue approved. 2000 Sanofi Aventis Lantus insulin "glargine" analogue approved for clinical use in the US and the EU. 2004 Sanofi Aventis Apidra insulin "glulisine" insulin analogue approved for clinical use in the US. 2006 Novo Nordisk Levemir "detemir" insulin analogue approved for clinical use in the US. 2008 Abbott laboratories " FreeStyle Navigator CGM" gets approved. 2013 The US Food and Drug Administration (FDA) requested more cardiac safety tests for Insulin degludec. 2015 Insulin degludec was approved by the FDA in September 2015.
There are 203 possible ways that the exchangeability parameters can be restricted to form sub-models of GTR, ranging from the JC69 and F81 models (where all exchangeability parameters are equal) to the SYM model and the full GTR (or REV) model (where all exchangeability parameters are free). The equilibrium base frequencies are typically treated in two different ways: 1) all
=== Monocyte activation test === The monocyte activation test (MAT) uses the monocytes in human blood in vitro to detect pyrogens. It was added to the European Pharmacopoeia in 2010 and accepted by the FDA in 2012.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.